';
Authors Posts by Jason Snyder

Jason Snyder

315 POSTS 0 COMMENTS

0 1272

In early 2017, the Pennsylvania Department of Drug and Alcohol Programs (DDAP) announced the beginning of a major transition to the ASAM Criteria, a comprehensive set of guidelines governing the level of care most appropriate for patients and the services provided at those levels. Improved quality of care through outcome-oriented and results-based treatment was among the many changes this transition promised.

DDAP cited several reasons for the change, from ensuring the necessary federal Medicaid funding through an 1115 waiver to support the continuation of residential services, to the consistency that the most widely used system would bring to the Pennsylvania provider and payer world.

Today, the commonwealth’s addiction treatment system is little more than four months away from DDAP’s July 1 deadline for implementation, yet providers still have questions about the specifics of many of the changes taking place. Some of these changes go beyond ASAM Criteria, creating additional questions and confusion.

And as providers analyze the cost implications of the change, driven by increases in required treatment services, decreases in counselor-to-patient ratios, and requirements for more highly trained counselors, therapists, and doctors, it is becoming clear to them how significant those costs will be. With no plan from the commonwealth to increase reimbursement rates to cover these mandates and a funding environment in which reimbursement is already often inadequate in comparison to costs, providers are frustrated. Some have lamented the possible closure of facilities because of the exorbitant cost increases. Yet perhaps most troubling, at a time when the Covid pandemic is helping to drive overdose deaths to a level not seen since the peak of the opioid overdose death epidemic in 2017, these costs could limit patient access to care.

Despite these issues, RCPA drug and alcohol treatment provider members support efforts to increase quality in Pennsylvania’s addiction treatment system. They recognize the strength of the ASAM Criteria. But to put their full support behind ASAM, they need reimbursement increases to cover the costs and favorable resolution of the mandates that go beyond the ASAM Criteria in a way that seriously considers provider input.

RCPA enjoys and appreciates strong working relationships with DDAP, the Department of Human Services and its Office of Mental Health and Substance Abuse Services, county drug and alcohol administrators, and the commonwealth’s Medicaid managed care organizations. In the spirit of avoiding any unintended consequences and ensuring a quality system is available to continue to treat all Pennsylvanians in need of addiction treatment services at all levels of care, RCPA will continue to collaborate with these groups to highlight the issues and identify and work toward solutions, all the while bringing to bear its resources to effect these changes on behalf of its members.

Photo by Alena Shekhovtcova from Pexels

The American Association for the Treatment of Opioid Dependence (AATOD) has asked the National Governors’ Association to encourage the country’s governors to include opioid treatment programs (OTPs) in the first round of Covid vaccination distribution. AATOD is also recommending that OTPs, which operate under the oversight of the Substance Abuse and Mental Health Services Administration (SAMHSA) and state opioid treatment authorities, including the Pennsylvania Department of Drug and Alcohol Programs (DDAP), get access to Covid vaccinations to inoculate their patients. Many patients treated in OTPs are medically vulnerable with medical co-morbidities. More information can be found here.

For those interested in supporting early intervention and treatment services for people with substance use disorder, and those at risk for developing these disorders, the Pennsylvania Department of Drug and Alcohol Programs (DDAP) and the University of Pittsburgh School of Pharmacy Program Evaluation and Research Unit (PERU) is presenting a two-part Screening, Brief Intervention, and Referral to Treatment (SBIRT) training and implementation series. More information and registration are available here.

In keeping with the Pennsylvania Department of Drug and Alcohol Program’s (DDAP) mandate that all addiction treatment providers contracted with behavioral health Medicaid managed care organizations or Single County Authorities provide treatment in alignment with the American Society of Addiction Medicine (ASAM) guidelines, Beacon Health Options has issued an alert summarizing the key aspects of the ASAM criteria.

DDAP has set July 1, 2021, as the deadline for ASAM implementation.

RCPA continues to work with its D&A members to understand the significant effects this change will have on their ability to continue to operate. In addition, RCPA continues to work with regulatory agencies and the legislature to make them aware of the extreme challenges this mandate has created and its potential effect on access to care for Pennsylvanians in need of treatment for substance use disorder.

Beacon’s alert can be viewed here. Questions for Beacon can be directed to the provider’s field coordinator.